What Exelixis, Inc. told the SEC could break it.

Substantially all of Exelixis's product revenue and gross margin derive from cabozantinib (CABOMETYX) — its cost of goods sold consists primarily of a 3% royalty payable on all net sales of any product containing cabozantinib — leaving the company heavily exposed to that single franchise's demand, competition and patent life.

“Cost of goods sold is related to our product revenues and consists primarily of a 3 % royalty we are required to pay on all net sales of any product containing cabozantinib, the cost of manufacturing, indirect labor costs, write-downs related to expiring and excess inventory, shipping and other third-party logistics and distribution costs for our product.”

Outside the US — including major EU markets and Japan — pricing and reimbursement of prescription pharmaceuticals is subject to significant governmental control and cost-control initiatives, which could delay marketing and pressure prices of Exelixis's (partner-commercialized) products, reducing royalty revenue.

“Outside the U.S., including major markets in the EU and Japan, the pricing and reimbursement of prescription pharmaceuticals is generally subject to significant governmental control.”

Exelixis sells its products principally to a limited set of specialty distributors and specialty pharmacy providers (which resell to providers/patients), concentrating its US product-revenue collection and channel risk in those intermediaries.

“We sell our products principally to specialty distributors and specialty pharmacy providers, or collectively, our Customers. These Customers subsequently resell our products to health care providers and patients.”